疫苗失败后住院的老年COVID-19患者的临床特征与结局
患者中位年龄84岁,61.2%超过80岁,总体死亡率为25.6%,80岁以上者为30.6%。较高的死亡率与年龄较大和接受托珠单抗治疗显著相关。
要点
- 纳入160例65岁以上疫苗失败后住院的COVID-19患者,中位年龄84岁。
- 总体死亡率为25.6%,80岁以上患者死亡率为30.6%。
- 较高死亡率与年龄较大及接受托珠单抗治疗显著相关。
核心结论
- 尽管COVID-19疫苗继续保护老年患者免于住院和死亡,并可能改善突破性感染患者住院后的预后,但该人群的死亡率仍然很高,尤其是80岁以上者。
主要发现
- 纳入患者中位年龄84岁,61.2%超过80岁,50.6%为男性,82.5%至少有一种合并症。
- 高达84%的患者接受了针对COVID-19的特异性治疗,其中76.9%接受低流量氧疗。
- 总体死亡率为25.6%,80岁以上患者死亡率为30.6%。
- 较高的死亡率与年龄较大和接受托珠单抗治疗显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We described clinical characteristics and outcome of 160 patients over 65 years (01 September to 31 August 2021) who had a first positive SARS-CoV-2 PCR- test more than 14 days after full vaccination and were hospitalized with COVID-19. Median age of included patients was 84 years, 61.2% were over 80 years; 50.6% were male and most (82.5%) has at least one comorbidity. Up to 84% received specific treatment against COVID-19, including 76.9% low-flow oxygen therapy. We found that overall mortality was 25.6% and 30.6% in those older than 80 years. A higher mortality was significantly associated with older age and treatment with tocilizumab. Our data showed that although COVID-19 vaccines continue protecting elderly patients against hospitalization and death and might improve the prognosis after hospitalization in patients with breakthrough infections, mortality in this population -especially in those older than 80 years- remains very high.
引用
- Díaz-Menéndez M, de la Calle-Prieto F, Montejano R, et al. Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure. Vaccine. 2022. PMID: 35701328. doi:10.1016/j.vaccine.2022.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。